Surgical treatment of intrahepatic cholangiocarcinoma: Four patients surviving more than five years

J. Yamamoto, T. Kosuge, T. Takayama, K. Shimada, M. Makuuchi, J. Yoshida, Michiie Sakamoto, S. Hirohashi, S. Yamasaki, H. Hasegawa

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

Background. To find the rational surgical strategy for the treatment of intrahepatic cholangiocarcinoma (ICC), clinical features of ICC were studied in 20 patients who underwent hepatic resection in the National Cancer Center Hospital from 1980 to 1990. Methods. According to the morphologic pattern, we classified the ICCs into two subcategories, mass-forming and infiltrating, which correlated with their biologic behavior. Results. Of 10 patients who underwent hepatectomy for mass-forming ICC, three survived more than 5 years without recurrence. The 1-, 3-, and 5-year survival rates were 59.3%, 44.4%, and 44.4%, respectively. Of 10 patients who underwent hepatectomy for infiltrating ICC, one survived more than 5 years without recurrence. The 1-, 3-, and 5-year survival rates were 72.0%, 27.0%, and 27.0%, respectively. The pathologic findings and recurrences indicated that the salient feature of the mass-forming type was its tendency for intrahepatic metastasis especially near a main lesion, and of the infiltrating type was the infiltrative spread via Glisson's capsule and hilar lymph nodal metastasis. Conclusions. An anatomic and extensive liver resection should be performed for mass-forming ICC, whereas a hepatectomy with excision of the extrahepatic bile duct and hilar lymph nodal dissection is recommended for infiltrating ICC.

Original languageEnglish
Pages (from-to)617-622
Number of pages6
JournalSurgery
Volume111
Issue number6
Publication statusPublished - 1992
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Surgery

Cite this

Yamamoto, J., Kosuge, T., Takayama, T., Shimada, K., Makuuchi, M., Yoshida, J., Sakamoto, M., Hirohashi, S., Yamasaki, S., & Hasegawa, H. (1992). Surgical treatment of intrahepatic cholangiocarcinoma: Four patients surviving more than five years. Surgery, 111(6), 617-622.